Innovating.works Conecta tu I+D

Showing 1 to 20 of 47 results

TETRIS: Risk assessment Tools for severe side Effects after breasT Radiotherapy: radiation safety through b... FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI tramitó un HORIZON EUROPE: HORIZON-EURATOM-2023-NRT-01 Radiation protection and safety measures are essential to ensure adequate quality & safety in radiotherapy (RT). Side effects are systematic...
2024-10-01 - 2027-09-30 | Financiado

TETRIS: Risk assessment Tools for severe side Effects after breasT Radiotherapy radiation safety through b... Radiation protection and safety measures are essential to ensure adequate quality & safety in radiotherapy (RT). Side effects are systematic...
2024-06-28 - 2027-09-30 | Financiado

EUonQoL: Quality of Life in Oncology: measuring what matters for cancer patients and survivors in Europe FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI tramitó un HORIZON EUROPE: HORIZON-MISS-2021-CANCER-02 EUonQoL aims to develop, pilot and validate the EUonQoL-Kit, a patient-driven, unified system for the assessment of quality of life (QoL) ba...
2023-01-01 - 2026-12-31 | Financiado

DISRUPT: On-chip tomographic microscopy: a paraDIgm Shift for RevolUtionizing lab-on-a-chiP bioimaging techno... FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI participó en un HORIZON EUROPE: HORIZON-EIC-2022-PATHFINDEROPEN-01 DISRUPT aims at revolutionising the field of biomedical imaging by developing a radically new lab-a-on-chip technology: integrated tomograph...
2022-12-15 - 2025-11-30 | Financiado

MELCAYA: Novel health care strategies for melanoma in children adolescents and young adults FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI participó en un HORIZON EUROPE: HORIZON-MISS-2021-CANCER-02 "In childhood, adolescence and young adults (CAYA), melanoma is under-studied and non-existing tailored clinical guidelines and standardized...
2022-12-01 - 2026-11-30 | Financiado

IDEA4RC: Intelligent Ecosystem to improve the governance, the sharing and the re-use of health Data for Rare... FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI tramitó un HORIZON EUROPE: HORIZON-HLTH-2021-TOOL-06 "The main objective of this project is to establish a Data Space for rare cancers (RC) that will make possible the re-use of existing multis...
2022-09-01 - 2026-08-31 | Financiado

INSPIRE: INtegrated Short-term PallIative REhabilitation to improve quality of life and equitable care access... FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI participó en un HORIZON EUROPE: HORIZON-HLTH-2021-DISEASE-04 Disability related to incurable cancer affects over a million Europeans each year. Our objective is to test the clinical and cost effectiven...
2022-07-28 - 2026-08-31 | Financiado

EU NAVIGATE: Implementation and evaluation of a Navigation Intervention for People with Cancer in Old Age and the... FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI participó en un HORIZON EUROPE: HORIZON-HLTH-2021-DISEASE-04 Background: Most people who have cancer are older people, affecting millions of Europeans each year. Providing high-quality, equitable, and...
2022-05-24 - 2027-08-31 | Financiado

I3LUNG: Integrative science, Intelligent data platform for Individualized LUNG cancer care with Immunotherap... FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI tramitó un HORIZON EUROPE: HORIZON-HLTH-2021-CARE-05 Immunotherapy (IO) is the new standard of care for many patients with advanced Non-Small Cell Lung Cancer (aNSCLC), yet only around 30-50% o...
2022-05-23 - 2027-05-31 | Financiado

MyPath: Developing and implementing innovative Patient Centred Care Pathways for cancer patients FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI participó en un HORIZON EUROPE: HORIZON-HLTH-2021-DISEASE-04 In the EU, 2.7M people were diagnosed with and 1.3M died of cancer in 2020. Over 12M people have survived cancer, thanks to advances in earl...
2022-05-20 - 2027-08-31 | Financiado

FORTEe: Get strong to fight childhood cancer an exercise intervention for children and adolescents undergoi... FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI participó en un H2020: H2020-SC1-BHC-2018-2020 Cancer is the first leading cause of death by non-communicable diseases in children in Europe. During cancer treatment, patients’ morbidity...
2021-02-03 - 2026-08-31 | Financiado

CCE_DART: Building Data Rich Clinical Trials FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI participó en un H2020: H2020-SC1-BHC-2018-2020 Successful drug approvals on Precision Oncology (PO) using basket studies have uncovered new challenges. Research in small patient populatio...
2021-01-18 - 2025-01-31 | Financiado

KATY: Knowledge At the Tip of Your fingers Clinical Knowledge for Humanity FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI participó en un H2020: H2020-SC1-FA-DTS-2018-2020 AI-empowered Personalized Medicine promises to find tailored, targeted, nearly hand-made cures for patients. Cancer treatment desperately ne...
2020-12-04 - 2024-12-31 | Financiado

CRIMSON: Coherent Raman Imaging for the Molecular Study of the OrigiN of diseases FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI participó en un H2020: H2020-ICT-2018-20 CRIMSON aims to provide a next-generation bio-photonics imaging device based on vibrational spectroscopy, with the potential to revolutionis...
2020-11-30 - 2024-05-31 | Financiado

X-eHealth: X eHealth eXchanging electronic Health Records in a commom framework FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI participó en un H2020: H2020-SC1-DTH-2018-2020 X-eHealth’s project stands herein for a project of strategic relevance for tomorrow’s European eHealth Union. Assembling at the time of this...
2020-06-04 - 2022-11-30 | Financiado

4-IN THE LUNG RUN: 4 IN THE LUNG RUN towards INdividually tailored INvitations screening INtervals and INtegrated co... FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI participó en un H2020: H2020-SC1-BHC-2018-2020 With 338,000 EU-deaths annually, lung cancer is a devastating problem. CT screening has the potential to prevent ten-thousands of lung cance...
2019-12-06 - 2024-12-31 | Financiado

BD4QoL: Big Data Models and Intelligent tools for Quality of Life monitoring and participatory empowerment o... FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI participó en un H2020: H2020-SC1-DTH-2018-2020 Head and neck cancer can take away a patient’s right to feel human, and its impact on physical appearance, physical functioning, psychologic...
2019-11-05 - 2024-12-31 | Financiado

SELNET: Sarcoma as a model to improve diagnosis and clinical care of rare tumors through a European and Lati... FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI participó en un H2020: H2020-SC1-BHC-2018-2020 Rare cancersRare cancers are associated with poor survival, accounting for 22% of new cancer diagnoses in Europe, and 30% of cancer deaths....
2018-12-14 - 2023-12-31 | Financiado

ONCOBIOME: Gut OncoMicrobiome Signatures GOMS associated with cancer incidence prognosis and prediction of t... FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI participó en un H2020: H2020-SC1-BHC-2018-2020 Beyond the role the intestinal metagenome plays in regulating multiple physBeyond its role in regulating multiple physiological functions th...
2018-12-03 - 2025-06-30 | Financiado

INT